Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Antiparkinson Agents/administration & dosage/adverse effects"'
Publikováno v:
Clinical Interventions in Aging
Clinical Interventions in Aging, Vol. 5 (2010) pp. 229-38
Clinical Interventions in Aging, Vol. 5 (2010) pp. 229-38
After more than 40 years of clinical use, levodopa (LD) remains the gold standard of symptomatic efficacy in the drug treatment of Parkinson's disease (PD). Compared with other available dopaminergic therapies, dopamine replacement with LD is associa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7de29a5bf30d7a429458377d4b5eba73
https://pubmed.ncbi.nlm.nih.gov/20852670
https://pubmed.ncbi.nlm.nih.gov/20852670
Autor:
E, Lohmann, S, Thobois, S, Lesage, E, Broussolle, S Tezenas, du Montcel, M-J, Ribeiro, P, Remy, A, Pelissolo, B, Dubois, L, Mallet, P, Pollak, Y, Agid, A, Brice, J-M, Warter
Publikováno v:
Neurology, Vol. 72, No 2 (2009) pp. 110-116
Objective: To establish phenotype–genotype correlations in early-onset Parkinson disease (EOPD), we performed neurologic, neuropsychological, and psychiatric evaluations in a series of patients with and without parkin mutations.Background: Parkin (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23e97720e15dc65f5d5b0c523b4d1e07
https://europepmc.org/articles/PMC2677494/
https://europepmc.org/articles/PMC2677494/
Autor:
Jean-Guy Villemure, P Combrement, H. Russmann, François Vingerhoets, J. Ghika, Pierre Burkhard, Julien Bogousslavsky
Publikováno v:
Neurology, Vol. 63, No 1 (2004) pp. 153-5
The authors studied the long-term evolution of levodopa-induced dyskinesia (LID) after levodopa challenge in two groups of six STN-deep brain stimulation-treated Parkinson disease (PD) patients, one requiring medication after surgery and the other no
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cbfa5574ccdab2d3e28d98c76904539
https://archive-ouverte.unige.ch/unige:45356
https://archive-ouverte.unige.ch/unige:45356
Autor:
Wolfgang H. Oertel, Delia Lorenz, Karin Berger, Richard Dodel, Volker Sturm, Paul Krack, D. Hellwig, E. A. Spottke, A Smala, H.-J. Freund, A. Gerstner, Jens Volkmann, Günther Deuschl
Publikováno v:
Journal of Neurology, Vol. 249, No 6 (2002) pp. 759-766
To assess the effects on motor functioning, health status and direct medical costs of high-frequency stimulation of the subthalamic nucleus (DBS-STN) in patients with idiopathic Parkinson's disease (PD). In addition, the cost-effectiveness of DBS-STN
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::029ca06ac32dc2c8fd0c58d168ab56e7
https://archive-ouverte.unige.ch/unige:95877
https://archive-ouverte.unige.ch/unige:95877
Autor:
Spiridon Konitsiotis, William Bara-Jimenez, Thomas N. Chase, Holly Shill, Marge Gillespie, Leo Verhagen Metman, Francesco Bibbiani, Carrie M. Farmer, M. Maral Mouradian, M. J. Morris
The objective of the study was to determine the safety and efficacy of increasing doses of Rotigotine CDS in patients with advanced Parkinson's disease. The development of motor complications in Parkinson's disease has been linked to intermittent sti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af66509f005bf089ad036320f61d4a41
http://olympias.lib.uoi.gr/jspui/handle/123456789/22813
http://olympias.lib.uoi.gr/jspui/handle/123456789/22813
Autor:
Patricia Limousin, Pierre Pollak, Abdelhamid Benazzouz, Alim-Louis Benabid, Paul Krack, Dominique Hoffmann
Publikováno v:
Movement Disorders, Vol. 13, No 4 (1998) pp. 648-52
We report three patients with bilateral GPi stimulation for stage 4 Parkinson's disease (PD) with severe levodopa-induced dyskinesias (LID). In all three it was possible to completely inhibit LID using high-stimulation parameters. Parallel to complet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99a45b9da1d3eb5932cd691735259704
https://archive-ouverte.unige.ch/unige:94636
https://archive-ouverte.unige.ch/unige:94636
The antidyskinetic potential of the glutamate NMDA receptor channel blocker amantadine was evaluated in four levodopa-primed parkinsonian monkeys using two different regimens (1.25 or 2.5 mg/kg administered subcutaneously twice daily for 3-6 days). W
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76b7a1d54e8c58c00b88df6f3b2e1f0d
http://olympias.lib.uoi.gr/jspui/handle/123456789/23946
http://olympias.lib.uoi.gr/jspui/handle/123456789/23946